Eficacia de ustekinumab en el tratamiento de la psoriasis moderada-grave
Efficacy of Ustekinumab in the Treatment of Moderate-Severe Psoriasis
R. Jiménez-Puya
, J.C. Moreno
Autor para correspondencia
Servicio de Dermatología. Hospital Universitario Reina Sofía. Córdoba. España
Leído
5919
Vecesse ha leído el artículo
2467
Total PDF
3452
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 61 | 114 | 175 |
| 2025 5 | 79 | 54 | 133 |
| 2025 4 | 94 | 39 | 133 |
| 2025 3 | 98 | 47 | 145 |
| 2025 2 | 59 | 28 | 87 |
| 2025 1 | 41 | 30 | 71 |
| 2024 12 | 46 | 19 | 65 |
| 2024 11 | 52 | 65 | 117 |
| 2024 10 | 43 | 37 | 80 |
| 2024 9 | 55 | 28 | 83 |
| 2024 8 | 51 | 55 | 106 |
| 2024 7 | 72 | 27 | 99 |
| 2024 6 | 58 | 51 | 109 |
| 2024 5 | 49 | 31 | 80 |
| 2024 4 | 44 | 36 | 80 |
| 2024 3 | 45 | 37 | 82 |
| 2024 2 | 30 | 33 | 63 |
| 2024 1 | 23 | 23 | 46 |
| 2023 12 | 19 | 14 | 33 |
| 2023 11 | 23 | 26 | 49 |
| 2023 10 | 13 | 9 | 22 |
| 2023 9 | 37 | 35 | 72 |
| 2023 8 | 23 | 23 | 46 |
| 2023 7 | 33 | 30 | 63 |
| 2023 6 | 27 | 28 | 55 |
| 2023 5 | 10 | 8 | 18 |
| 2023 4 | 18 | 13 | 31 |
| 2023 3 | 19 | 20 | 39 |
| 2023 2 | 15 | 18 | 33 |
| 2022 1 | 17 | 29 | 46 |
| 2022 12 | 30 | 26 | 56 |
| 2022 11 | 31 | 28 | 59 |
| 2022 10 | 35 | 27 | 62 |
| 2022 9 | 21 | 30 | 51 |
| 2022 8 | 42 | 37 | 79 |
| 2022 7 | 33 | 35 | 68 |
| 2022 6 | 20 | 25 | 45 |
| 2022 5 | 36 | 43 | 79 |
| 2022 4 | 31 | 29 | 60 |
| 2022 3 | 35 | 50 | 85 |
| 2022 2 | 17 | 26 | 43 |
| 2021 1 | 20 | 41 | 61 |
| 2021 12 | 29 | 49 | 78 |
| 2021 11 | 25 | 47 | 72 |
| 2021 10 | 34 | 49 | 83 |
| 2021 9 | 22 | 39 | 61 |
| 2021 8 | 37 | 34 | 71 |
| 2021 7 | 24 | 31 | 55 |
| 2021 6 | 21 | 41 | 62 |
| 2021 5 | 23 | 46 | 69 |
| 2021 4 | 52 | 55 | 107 |
| 2021 3 | 30 | 38 | 68 |
| 2021 2 | 34 | 24 | 58 |
| 2020 1 | 17 | 16 | 33 |
| 2020 12 | 23 | 19 | 42 |
| 2020 11 | 29 | 15 | 44 |
| 2020 10 | 17 | 14 | 31 |
| 2020 9 | 16 | 8 | 24 |
| 2020 8 | 28 | 12 | 40 |
| 2020 7 | 22 | 17 | 39 |
| 2020 6 | 17 | 22 | 39 |
| 2020 5 | 22 | 21 | 43 |
| 2020 4 | 19 | 21 | 40 |
| 2020 3 | 22 | 24 | 46 |
| 2020 2 | 1 | 3 | 4 |
| 2019 12 | 0 | 1 | 1 |
| 2019 11 | 0 | 2 | 2 |
| 2019 10 | 0 | 1 | 1 |
| 2019 9 | 0 | 3 | 3 |
| 2019 7 | 0 | 2 | 2 |
| 2019 6 | 0 | 3 | 3 |
| 2019 5 | 1 | 12 | 13 |
| 2019 2 | 0 | 1 | 1 |
| 2019 1 | 0 | 1 | 1 |
| 2018 12 | 0 | 3 | 3 |
| 2018 11 | 0 | 7 | 7 |
| 2018 10 | 0 | 1 | 1 |
| 2018 9 | 1 | 0 | 1 |
| 2018 3 | 2 | 0 | 2 |
| 2018 2 | 54 | 5 | 59 |
| 2018 1 | 42 | 3 | 45 |
| 2017 12 | 40 | 10 | 50 |
| 2017 11 | 35 | 4 | 39 |
| 2017 10 | 30 | 6 | 36 |
| 2017 9 | 22 | 5 | 27 |
| 2017 8 | 48 | 6 | 54 |
| 2017 7 | 43 | 6 | 49 |
| 2017 6 | 56 | 6 | 62 |
| 2017 5 | 40 | 11 | 51 |
| 2017 4 | 51 | 8 | 59 |
| 2017 3 | 26 | 16 | 42 |
| 2017 2 | 33 | 5 | 38 |
| 2016 1 | 35 | 8 | 43 |
| 2016 12 | 35 | 6 | 41 |
| 2016 11 | 54 | 7 | 61 |
| 2016 10 | 54 | 8 | 62 |
| 2016 9 | 53 | 10 | 63 |
| 2016 8 | 60 | 13 | 73 |
| 2016 7 | 31 | 7 | 38 |
| 2016 5 | 0 | 11 | 11 |
| 2016 4 | 1 | 0 | 1 |
| 2016 2 | 0 | 3 | 3 |
| 2015 1 | 0 | 18 | 18 |
| 2015 12 | 0 | 18 | 18 |
| 2015 11 | 8 | 12 | 20 |
| 2015 10 | 2 | 7 | 9 |
| 2015 9 | 10 | 13 | 23 |
| 2015 8 | 2 | 7 | 9 |
| 2015 7 | 37 | 3 | 40 |
| 2015 6 | 26 | 4 | 30 |
| 2015 5 | 65 | 28 | 93 |
| 2015 4 | 38 | 14 | 52 |
| 2015 3 | 39 | 9 | 48 |
| 2015 2 | 38 | 12 | 50 |
| 2015 1 | 31 | 14 | 45 |
| 2014 12 | 60 | 8 | 68 |
| 2014 11 | 32 | 12 | 44 |
| 2014 10 | 35 | 25 | 60 |
| 2014 8 | 1 | 0 | 1 |
| 2014 5 | 1 | 0 | 1 |
| 2014 1 | 2 | 2 | 4 |
| 2013 10 | 1 | 0 | 1 |
| 2013 9 | 0 | 1 | 1 |
| 2013 6 | 5 | 5 | 10 |
| 2013 5 | 1 | 1 | 2 |
| 2013 4 | 1 | 1 | 2 |
| 2013 3 | 1 | 1 | 2 |
| 2013 2 | 0 | 1 | 1 |
| 2013 1 | 0 | 1 | 1 |
Mostrar todo
